-X-R_5,

-X-N(R_6)-Y-R_4,

-X-C(R_7)-N(R_6)-R_4, and

-X-O-R_4;

or R_1' and R_1 together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



, 

, and 

;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R_4 is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R_1 is bonded;

R_5 is selected from the group consisting of:



, 

, and 

;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

R_7 is selected from the group consisting of =O and =S;

R_8 is C_{2-7} alkylene;

A is selected from the group consisting of -CH(R_6)-, -O-, -N(R_6)-, -N(Y-R_4)-, and -N(X-N(R_6)-Y-R_4)-;

X is C_{2-20} alkylene;

Y is selected from the group consisting of -C(R_7)-, -C(R_7)-O-, -S(O)$_2$-,

$-S(O)_2-N(R_6)-$, and $-C(R_7)-N(R_9)-$; wherein R_9 is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or R_9 and R_4 together with the nitrogen atom to which R_9 is bonded can join to form the group



;

a and b are independently integers from 1 to 4 with the proviso that when A is $-O-$, $-N(R_6)-$, $-N(Y-R_4)-$, or $-N(X-N(R_6)-Y-R_4)-$ then a and b are independently integers from 2 to 4; and

R" is hydrogen or a non-interfering substituent;

or a pharmaceutically acceptable salt thereof.

6. The compound or salt of claim 5 wherein the compound or salt induces the biosynthesis of one or more cytokines.

7. A compound of the Formula (I-1):



I-1

wherein:

R_1' is selected from the group consisting of hydrogen and alkyl;

R_1 is selected from the group consisting of:

$-R_4$,

$-Y-R_4$,

$-X-R_5$,

$-X-N(R_6)-Y-R_4$,

$-X-C(R_7)-N(R_6)-R_4$, and

$-X-O-R_4$;

or R_1' and R_1 together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



;

R_2 is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,

-halogen,

$-N(R_6)_2$,

$-C(R_7)-N(R_6)_2$,

$-S(O)_2-N(R_6)_2$,

$-N(R_6)-C(R_7)-C_{1-10}$ alkyl,

$-N(R_6)-S(O)_2-C_{1-10}$ alkyl,

$-C(O)-C_{1-10}$ alkyl,

$-C(O)-O-C_{1-10}$ alkyl,

$-N_3$,

-aryl,

-heteroaryl,

-heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

R_3 is selected from the group consisting of:

-Z'-R_4',

-Z'-X'-R_4',

-Z'-X'-Y'-R_4', and

-Z'-X'-R_5';

each R is independently selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, fluoroalkyl, hydroxy, amino, alkylamino, and dialkylamino;

n is an integer from 0 to 4;

m is 0 or 1; with the proviso that when m is 1, then n is 0 or 1;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R_4 is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R_1 is bonded;

R_5 is selected from the group consisting of:


, 
, and 
;

X is C_{2-20} alkylene;

Y is selected from the group consisting of -C(R_7)-, -C(R_7)-O-, -S(O)$_2$-, -S(O)$_2$-N(R_6)-, and -C(R_7)-N(R_9)-; wherein R_9 is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or R_9 and R_4 together with the nitrogen atom to which R_9 is bonded can join to form the group


;

Z is selected from the group consisting of -O- and -$S(O)_{0-2}$-;

A is selected from the group consisting of -$CH(R_6)$-, -O-, -$N(R_6)$-, -$N(Y\text{-}R_4)$-, and -$N(X\text{-}N(R_6)\text{-}Y\text{-}R_4)$-;

a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -$N(R_6)$-, -$N(Y\text{-}R_4)$-, or -$N(X\text{-}N(R_6)\text{-}Y\text{-}R_4)$- then a and b are independently integers from 2 to 4;

R_4' is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R_5' is selected from the group consisting of:



;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene, or heterocyclylene and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:

-$S(O)_{0-2}$-,

-$S(O)_2$-$N(R_{11})$-,

-$C(R_7)$-,

-$C(R_7)$-O-,

-O-$C(R_7)$-,

-O-C(O)-O-,

$-N(R_{11})-Q-$,

$-C(R_7)-N(R_{11})-$,

$-O-C(R_7)-N(R_{11})-$,

$-C(R_7)-N(OR_{12})-$,



,



,



,



, and



;

Z' is a bond or -O-;

A' is selected from the group consisting of $-CH_2-$, -O-, -C(O)-, $-S(O)_{0-2}-$, and $-N(R_4')-$;

Q is selected from the group consisting of a bond, $-C(R_7)-$, $-C(R_7)-C(R_7)-$, $-S(O)_2-$, $-C(R_7)-N(R_{11})-W-$, $-S(O)_2-N(R_{11})-$, $-C(R_7)-O-$, and $-C(R_7)-N(OR_{12})-$;

V is selected from the group consisting of $-C(R_7)-$, $-O-C(R_7)-$, $-N(R_{11})-C(R_7)-$, and $-S(O)_2-$;

W is selected from the group consisting of a bond, -C(O)-, and $-S(O)_2-$;

c and d are independently integers from 1 to 6 with the proviso that c + d is ≤ 7, and when A' is -O- or $-N(R_4')-$ then c and d are independently integers from 2 to 4;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

each R_7 is independently selected from the group consisting of =O and =S;

each R_8 is independently C_{2-7} alkylene;

R_{10} is C_{3-8} alkylene;

each R_{11} is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{1-10} alkoxyC_{2-10} alkylenyl, and arylC_{1-10} alkylenyl; and

R_{12} is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

8. The compound or salt according to claim 7 wherein R_1 is selected from the group consisting of $-R_4$, $-Y-R_4$, and $-X-N(R_6)-Y-R_4$ wherein Y is $-C(R_7)-$, $-S(O)_2-$, or $-C(R_7)-N(R_9)-$.

9. The compound or salt according to claim 8 wherein R_1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, heterocyclylcarbonylaminoalkylenyl, and arylaminocarbonylaminoalkylenyl.

10. The compound or salt according to claim 9 wherein R_1 is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl, cyclohexyl, benzyl, 3-phenylpropyl, cinnamyl, furan-2-ylmethyl, and $-CH_2CH_2CH_2-NHR_{13}$, wherein R_{13} is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, isopropylaminocarbonyl, morpholine-4-carbonyl, and phenylaminocarbonyl.

11. The compound or salt according to claim 7 wherein R_1' is hydrogen.

12. The compound or salt of claim 7 wherein R_1 and R_1' are each independently alkyl.

13. The compound or salt of claim 7 wherein R_1 and R_1' join to form the group:



14. The compound or salt according to claim 7 wherein R_2 is selected from the group consisting of hydrogen, alkyl, and alkoxyalkylenyl.

15. The compound or salt according to claim 14 wherein R_2 is selected from the group consisting of hydrogen, methyl, propyl, butyl, 2-methoxyethyl, and ethoxymethyl.

16. The compound or salt according to claim 7 wherein n is 0.

17. The compound or salt according to claim 7 wherein n is 0, and R_3 is selected from the group consisting of -Z'-R_4', -Z'-X'-R_4', and -Z'-X'-Y'-R_4'.

18. The compound or salt according to claim 17 wherein R_3 is selected from the group consisting of 2-(pyridin-3-yl)ethyl, pyridinyl, hydroxymethylpyridinyl, ethoxyphenyl, (morpholine-4-carbonyl)phenyl, 2-(methanesulfonylamino)ethoxy, and benzyloxy.

19. A compound of the Formula (I-2):



I-2

wherein:

R_B is selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;

n is an integer from 0 to 4;

R_1' is selected from the group consisting of hydrogen and alkyl;

R_1 is selected from the group consisting of:

-R_4,

-Y-R_4,

-X-R_5,

-X-N(R_6)-Y-R_4,

-X-C(R_7)-N(R_6)-R_4, and

-X-O-R_4;

or R_1' and R_1 together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



, 

, and 

;

R_2 is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,

-halogen,

-N(R_6)$_2$,

-C(R_7)-N(R_6)$_2$,

-S(O)$_2$-N(R_6)$_2$,

-N(R_6)-C(R_7)-C_{1-10} alkyl,

-N(R_6)-S(O)$_2$-C_{1-10} alkyl,

-C(O)-C_{1-10} alkyl,

-C(O)-O-C_{1-10} alkyl,

-N_3,

-aryl,

-heteroaryl,

-heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R_4 is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R_1 is bonded;

R_5 is selected from the group consisting of:



, and ;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

each R_7 is independently selected from the group consisting of =O and =S;

R_8 is C_{2-7} alkylene;

A is selected from the group consisting of -CH(R_6)-, -O-, -N(R_6)-, -N(Y-R_4)-, and -N(X-N(R_6)-Y-R_4)-;

X is C_{2-20} alkylene;

Y is selected from the group consisting of -C(R_7)-, -C(R_7)-O-, -S(O)$_2$-, -S(O)$_2$-N(R_6)-, and -C(R_7)-N(R_9)-; wherein R_9 is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or R_9 and R_4 together with the nitrogen atom to which R_9 is bonded can join to form the group



;

Z is selected from the group consisting of -O- and -S(O)$_{0-2}$-; and

a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -N(R_6)-, -N(Y-R_4)-, or -N(X-N(R_6)-Y-R_4)- then a and b are independently integers from 2 to 4;
or a pharmaceutically acceptable salt thereof.

20. The compound or salt according to claim 19 wherein R_1 is selected from the group consisting of -R_4, -Y-R_4, and -X-N(R_6)-Y-R_4 wherein Y is -C(R_7)-, -S(O)$_2$-, or -C(R_7)-N(R_9)-.

21. The compound or salt according to claim 20 wherein R_1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, and arylaminocarbonylaminoalkylenyl.

22. The compound or salt according to claim 21 wherein R_1 is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl, cyclohexyl, benzyl, cinnamyl, furan-2-ylmethyl, and –$CH_2CH_2CH_2$-NHR_{13}, wherein R_{13} is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, and phenylaminocarbonyl.

23. The compound or salt according to claim 19 wherein R_1' is hydrogen.

24. The compound or salt of claim 19 wherein R_1 and R_1' are each independently alkyl.

25. The compound or salt of claim 19 wherein R_1 and R_1' join to form the group:



26. The compound or salt according to claim 19 wherein R_2 is selected from the group consisting of hydrogen, alkyl, and alkoxyalkylenyl.

27. The compound or salt according to claim 26 wherein R_2 is selected from the group consisting of hydrogen, butyl, 2-methoxyethyl, and ethoxymethyl.

28. The compound or salt according to claim 19 wherein n is 0.

29. The compound or salt according to claim 19 wherein n is 1, and R is halogen or hydroxy.

30. A compound of the Formula (I-3):



I-3

wherein:

R_B is selected from alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;

n is an integer from 0 to 4;

R_1' is selected from hydrogen and alkyl;

R_1 is selected from:

$-R_4$,

$-Y-R_4$,

$-X-R_5$,

$-X-N(R_6)-Y-R_4$,

$-X-CR_7-N(R_6)-R_4$, and

$-X-O-R_4$;

or R_1' and R_1 together with the nitrogen atom to which they are bonded can join to form a group selected from:



, and 
;

R_{2A} is selected from:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z- alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from:

-OH,

-halogen,

$-N(R_6)_2$,

$-CR_7-N(R_6)_2$,

$-SO_2-N(R_6)_2$,

$-N(R_6)-CR_7-C_{1-10}$ alkyl,

$-N(R_6)-SO_2-C_{1-10}$ alkyl,

$-C(O)-C_{1-10}$ alkyl,

$-C(O)-O-C_{1-10}$ alkyl,

$-N_3$,

-aryl,

-heteroaryl,

-heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

R_4 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano,

carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R_4 is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R_1 is bonded;

R_5 is selected from:


, 
, and 
;

R_6 is selected from hydrogen, alkyl, and arylalkylenyl;

R_7 is selected from =O and =S;

R_8 is C_{2-7} alkylene;

R_9 is selected from hydrogen, alkyl, and arylalkylenyl, or R_9 and R_4 together with the nitrogen atom to which R_9 is bonded can join to form the group


;

A is selected from $-CHR_6-$, -O-, $-N(R_6)-$, $-N(Y-R_4)-$, and $-N(X-N(R_6)-Y-R_4)-$;

X is C_{2-20} alkylene;

Y is selected from $-CR_7-$, $-SO_2-$, $-SO_2-N(R_6)-$, and $-CR_7-N(R_9)-$;

Z is selected from -O- and $-S(O)_{0-2}-$;

a and b are independently integers from 1 to 4 with the proviso that when A is -O-, $-N(R_6)-$, $-N(Y-R_4)-$, or $-N(X-N(R_6)-Y-R_4)-$ then a and b are independently integers from 2 to 4;

and pharmaceutically acceptable salts thereof.

31. The compound or salt according to claim 30 wherein R_1 is selected from $-R_4$, $-Y-R_4$, and $-X-N(R_6)-Y-R_4$ wherein Y is $-CR_7-$, $-SO_2-$, or $-CR_7-N(R_9)-$.

32. The compound or salt according to claim 31 wherein R_1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl,

heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, and arylaminocarbonylaminoalkylenyl.

33. The compound or salt according to claim 32 wherein R_1 is selected from hydrogen, isopropyl, butyl, cyclohexyl, benzyl, cinnamyl, and $-CH_2CH_2CH_2-NHR_{13}$, wherein R_{13} is selected from methanesulfonyl, phenylsulfonyl, benzyl, and phenylaminocarbonyl.

34. The compound or salt according to claim 30 wherein R_1' is hydrogen.

35. The compound or salt according to claim 30 wherein R_{2A} is selected from hydrogen, alkyl, and alkoxyalkylenyl.

36. The compound or salt according to claim 35 wherein R_{2A} is selected from hydrogen, butyl, methoxyethyl, and ethoxymethyl.

37. The compound or salt according to claim 30 wherein n is 0.

38. A compound of the Formula (II-1):



II-1

wherein:

each R_A is independently selected from the group consisting of:

halogen,

hydroxy,

alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio,
$-NH_2$,
-NH(alkyl), and
$-N(alkyl)_2$;

n is an integer from 0 to 4;

R_1' is selected from the group consisting of hydrogen and alkyl;

R_1 is selected from the group consisting of:

$-R_4$,
$-Y-R_4$,
$-X-R_5$,
$-X-N(R_6)-Y-R_4$,
$-X-C(R_7)-N(R_6)-R_4$, and
$-X-O-R_4$;

or R_1' and R_1 together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:


, 
, and 
;

R_2 is selected from the group consisting of:

-hydrogen,
-alkyl,
-alkenyl,
-aryl,
-heteroaryl,
-heterocyclyl,
-alkylene-Z-alkyl,
-alkylene-Z-aryl,
-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,
-halogen,
-$N(R_6)_2$,
-$C(R_7)$-$N(R_6)_2$,
-$S(O)_2$-$N(R_6)_2$,
-$N(R_6)$-$C(R_7)$-C_{1-10} alkyl,
-$N(R_6)$-$S(O)_2$-C_{1-10} alkyl,
-$C(O)$-C_{1-10} alkyl,
-$C(O)$-O-C_{1-10} alkyl,
-N_3,
-aryl,
-heteroaryl,
-heterocyclyl,
-C(O)-aryl, and
-C(O)-heteroaryl;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R_4 is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R_1 is bonded;

R_5 is selected from the group consisting of:



,


, and


;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

each R_7 is independently selected from the group consisting of =O and =S;

R_8 is C_{2-7} alkylene;

A is selected from the group consisting of -CH(R_6)-, -O-, -N(R_6)-, -N(Y-R_4)-, and -N(X-N(R_6)-Y-R_4)-;

X is C_{2-20} alkylene;

Y is selected from the group consisting of -C(R_7)-, -C(R_7)-O-, -S(O)$_2$-, -S(O)$_2$-N(R_6)-, and -C(R_7)-N(R_9)-; wherein R_9 is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or R_9 and R_4 together with the nitrogen atom to which R_9 is bonded can join to form the group



;

Z is selected from the group consisting of -O- and -S(O)$_{0-2}$-; and

a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -N(R_6)-, -N(Y-R_4)-, or -N(X-N(R_6)-Y-R_4)- then a and b are independently integers from 2 to 4;

or a pharmaceutically acceptable salt thereof.

39. The compound or salt according to claim 38 wherein R_1 is selected from the group consisting of -R_4, -Y-R_4, and -X-N(R_6)-Y-R_4 wherein Y is -C(R_7)-, -S(O)$_2$-, or -C(R_7)-N(R_9)-.

40. The compound or salt according to claim 39 wherein R_1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, and arylaminocarbonylaminoalkylenyl.

41. The compound or salt according to claim 39 wherein R_1 is selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkylenyl, arylalkenylenyl, heteroarylalkylenyl, heteroarylalkenylenyl, aminoalkylenyl, alkoxyalkylenyl, acyl, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylaminocarbonyl, arylaminocarbonyl, (arylalkylenyl)aminoalkylenyl, heterocyclylcarbonylaminoalkylenyl, and arylaminocarbonylaminoalkylenyl.

42. The compound or salt according to claim 40 wherein R_1 is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl, cyclohexyl, benzyl, cinnamyl, furan-2-ylmethyl, and $-CH_2CH_2CH_2-NHR_{13}$, wherein R_{13} is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, and phenylaminocarbonyl.

43. The compound or salt according to claim 41 wherein R_1 is selected from the group consisting of hydrogen, methyl, isopropyl, butyl, 2-methylpropyl, 1-ethylpropyl, 3-methylbutyl, cyclohexyl, benzyl, 3-phenylpropyl, cinnamyl, furan-2-ylmethyl, and $-CH_2CH_2CH_2-NHR_{13}$, wherein R_{13} is selected from the group consisting of methanesulfonyl, phenylsulfonyl, benzyl, isopropylaminocarbonyl, morpholine-4-carbonyl, and phenylaminocarbonyl.

44. The compound or salt according to claim 38 wherein R_1' is hydrogen.

45. The compound or salt of claim 38 wherein R_1 and R_1' are each independently alkyl.

46. The compound or salt of claim 38 wherein R_1 and R_1' join to form the group:



47. The compound or salt according to claim 38 wherein R_2 is selected from the group consisting of hydrogen, alkyl, and alkoxyalkylenyl.

48. The compound or salt according to claim 47 wherein R_2 is selected from the group consisting of hydrogen, butyl, 2-methoxyethyl, and ethoxymethyl.

49. The compound or salt according to claim 47 wherein R_2 is selected from the group consisting of hydrogen, methyl, propyl, butyl, 2-methoxyethyl, and ethoxymethyl.

50. The compound or salt according to claim 38 wherein n is 0.

51. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.

52. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 5 and a pharmaceutically acceptable carrier.

53. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 7 and a pharmaceutically acceptable carrier.

54. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 19 and a pharmaceutically acceptable carrier.

55. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 30 and a pharmaceutically acceptable carrier.

56. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 38 and a pharmaceutically acceptable carrier.

57. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.

58. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 5 to the animal.

59. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 7 to the animal.

60. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 19 to the animal.

61. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 30 to the animal.

62. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 38 to the animal.

63. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 1.

64. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 5.

65. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 7.

66. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 19.

67. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 30.

68. A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 38.

69. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 1.

70. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 5.

71. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 7.

72. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 19.

73. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 30.

74. A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 38.

75. A compound of the Formula (VII):



VII

wherein:

each R_B is independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;

n is an integer from 0 to 4;

R_2 is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,
-halogen,
-$N(R_6)_2$,
-$C(R_7)$-$N(R_6)_2$,
-$S(O)_2$-$N(R_6)_2$,
-$N(R_6)$-$C(R_7)$-C_{1-10} alkyl,
-$N(R_6)$- $S(O)_2$-C_{1-10} alkyl,
-C(O)-C_{1-10} alkyl,
-C(O)-O-C_{1-10} alkyl,
-N_3,
-aryl,
-heteroaryl,
-heterocyclyl,
-C(O)-aryl, and
-C(O)-heteroaryl;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

R_7 is selected from the group consisting of =O and =S; and

Z is selected from the group consisting of -O- and -$S(O)_{0-2}$-;

or a pharmaceutically acceptable salt thereof.

76. A compound of the Formula (IX):



IX

wherein:

each R_B is independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;

n is an integer from 0 to 4;

R_1' is hydrogen or alkyl;

R_1 is selected from the group consisting of:

-R_4,

-Y-R_4,

-X-R_5,

-X-N(R_6)-Y-R_4,

-X-C(R_7)-N(R_6)-R_4, and

-X-O-R_4;

or R_1' and R_1 together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



,


, and


;

R_2 is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,

-halogen,

-N(R_6)$_2$,

-C(R_7)-N(R_6)$_2$,

-S(O)$_2$-N(R_6)$_2$,

-N(R_6)-C(R_7)-C_{1-10} alkyl,

-N(R_6)- S(O)$_2$-C_{1-10} alkyl,

-C(O)-C_{1-10} alkyl,

-C(O)-O-C_{1-10} alkyl,

-N_3,

-aryl,

-heteroaryl,

-heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R_4 is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R_1 is bonded;

R_5 is selected from the group consisting of



, , and ;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

each R_7 is independently selected from the group consisting of =O and =S;

R_8 is C_{2-7} alkylene;

A is selected from the group consisting of -$CH(R_6)$-, -O-, -$N(R_6)$-, -$N(Y\text{-}R_4)$-, and -$N(X\text{-}N(R_6)\text{-}Y\text{-}R_4)$-;

X is C_{2-20} alkylene;

Y is selected from the group consisting of -$C(R_7)$-, -$C(R_7)$-O-, -$S(O)_2$-,

$-S(O)_2-N(R_6)-$, and $-C(R_7)-N(R_9)-$; wherein R_9 is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or R_9 and R_4 together with the nitrogen atom to which R_9 is bonded can join to form the group



;

Z is selected from the group consisting of -O- and $-S(O)_{0-2}-$; and

a and b are independently integers from 1 to 4 with the proviso that when A is $-O-$, $-N(R_6)-$, $-N(Y-R_4)-$, or $-N(X-N(R_6)-Y-R_4)-$ then a and b are independently integers from 2 to 4;

or a pharmaceutically acceptable salt thereof.

77. A compound of the Formula (X):



X

wherein:

each R_B is independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, and trifluoromethyl;

n is an integer from 0 to 4;

R_1' is hydrogen or alkyl;

R_{1a} is selected from the group consisting of:

$-R_{4a}$,

$-Y-R_{4a}$,

$-X-R_5$,

$-X-N(R_6)-Y-R_{4a}$,

$-X-C(R_7)-N(R_6)-R_{4a}$, and

$-X-O-R_{4a}$;

or R_1' and R_{1a} together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



, , and ;

R_{2a} is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-alkylene-Z"-alkyl,

-alkylene-Z"-aryl,

-alkylene-Z"- alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,

-halogen,

$-N(R_6)_2$,

$-C(R_7)-N(R_6)_2$,

$-S(O)_2-N(R_6)_2$,

$-N(R_6)-C(R_7)-C_{1-10}$ alkyl,

$-N(R_6)-S(O)_2-C_{1-10}$ alkyl,

$-C(O)-C_{1-10}$ alkyl,

$-C(O)-O-C_{1-10}$ alkyl,

$-N_3$,

-aryl,

-heterocyclyl, and

-C(O)-aryl;

R_{4a} is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl,

and heterocyclyl, oxo, with the proviso that when R_{4a} is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R_1 is bonded;

R_5 is selected from the group consisting of



, and ;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

each R_7 is independently selected from the group consisting of =O and =S;

R_8 is C_{2-7} alkylene;

A is selected from the group consisting of -CH(R_6)-, -O-, -N(R_6)-, -N(Y-R_4)-, and -N(X-N(R_6)-Y-R_4)-;

X is C_{2-20} alkylene;

Y is selected from the group consisting of -C(R_7)-, -C(R_7)-O-, -S(O)$_2$-, -S(O)$_2$-N(R_6)-, and -C(R_7)-N(R_9)-; wherein R_9 is selected from the group consisting of hydrogen, alkyl and arylalkylenyl, or R_9 and R_4 together with the nitrogen atom to which R_9 is bonded can join to form the group



;

Z" is selected from the group consisting of -O- and -S(O)$_2$-; and

a and b are independently integers from 1 to 4 with the proviso that when A is -O-, -N(R_6)-, -N(Y-R_4)-, or -N(X-N(R_6)-Y-R_4)- then a and b are independently integers from 2 to 4;

or a pharmaceutically acceptable salt thereof.

78. A compound of the Formula (XLII):



XLII

wherein:

R is selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, fluoroalkyl, hydroxy, amino, alkylamino, and dialkylamino;

l is 0 or 1;

R_2 is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,

-halogen,

$-N(R_6)_2$,

$-C(R_7)-N(R_6)_2$,

$-S(O)_2-N(R_6)_2$,

$-N(R_6)-C(R_7)-C_{1-10}$ alkyl,

$-N(R_6)-S(O)_2-C_{1-10}$ alkyl,

$-C(O)-C_{1-10}$ alkyl,

-C(O)-O-C_{1-10} alkyl,

-N_3,

-aryl,

-heteroaryl,

-heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

R_7 is selected from the group consisting of =O and =S; and

Z is selected from the group consisting of -O- and -$S(O)_{0-2}$-;

or a pharmaceutically acceptable salt thereof.

79. A compound of the Formula (XLIII):



XLIII

wherein:

R is selected from the group consisting of alkyl, alkenyl, alkoxy, halogen, fluoroalkyl, hydroxy, amino, alkylamino, and dialkylamino;

l is 0 or 1;

R_1' is hydrogen or alkyl;

R_1 is selected from the group consisting of:

-R_4,

-Y-R_4,

-X-R_5,

-X-N(R_6)-Y-R_4,

-X-C(R_7)-N(R_6)-R_4, and

-X-O-R_4;

or R_1' and R_1 together with the nitrogen atom to which they are bonded can join to form a group selected from the group consisting of:



, 

, and 

;

R_2 is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkylene-Z-alkyl,

-alkylene-Z-aryl,

-alkylene-Z-alkenyl, and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,

-halogen,

-$N(R_6)_2$,

-$C(R_7)$-$N(R_6)_2$,

-$S(O)_2$-$N(R_6)_2$,

-$N(R_6)$-$C(R_7)$-C_{1-10} alkyl,

-$N(R_6)$- $S(O)_2$-C_{1-10} alkyl,

-C(O)-C_{1-10} alkyl,

-C(O)-O-C_{1-10} alkyl,

-N_3,

-aryl,

-heteroaryl,

-heterocyclyl,

-C(O)-aryl, and

-C(O)-heteroaryl;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkylenyl, amino, alkylamino, (arylalkylenyl)amino, dialkylamino, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo, with the proviso that when R_4 is a substituted alkyl group and the substituent contains a hetero atom which bonds directly to the alkyl group then the alkyl group contains at least two carbons between the substituent and the nitrogen atom to which R_1 is bonded;

R_5 is selected from the group consisting of


, 
, and 
;

each R_6 is independently selected from the group consisting of hydrogen, alkyl, and arylalkylenyl;

each R_7 is independently selected from the group consisting of =O and =S;

R_8 is C_{2-7} alkylene;

A is selected from the group consisting of $-CH(R_6)-$, -O-, $-N(R_6)-$, $-N(Y-R_4)-$, and $-N(X-N(R_6)-Y-R_4)-$;

X is C_{2-20} alkylene;

Y is selected from the group consisting of $-C(R_7)-$, $-C(R_7)-O-$, $-S(O)_2-$, $-S(O)_2-N(R_6)-$, and $-C(R_7)-N(R_9)-$; wherein R_9 is selected from the group consisting of hydrogen, alkyl, and arylalkylenyl; or R_9 and R_4 together with the nitrogen atom to which R_9 is bonded can join to form the group


;

Z is selected from the group consisting of -O- and $-S(O)_{0-2}-$; and

a and b are independently integers from 1 to 4 with the proviso that when A is

-O-, -N(R_6)-, -N(Y-R_4)-, or -N(X-N(R_6)-Y-R_4)- then a and b are independently integers from 2 to 4;

or a pharmaceutically acceptable salt thereof.

5